Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for vrx
130.38
+5.60 (4.49%)
Oct 21 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 126.35 - 131.78
52 week 102.60 - 153.10
Open 126.35
Vol / Avg. 3.94M/3.02M
Mkt cap 41.64B
P/E     -
Div/yield     -
EPS -2.25
Shares 333.78M
Beta 0.89
Inst. own 59%
Oct 20, 2014
Q3 2014 Valeant Pharmaceuticals International Inc Earnings Release
Oct 20, 2014
Q3 2014 Valeant Pharmaceuticals International Inc Earnings Call
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International, Inc. Earnings Release
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 5.98% -14.97%
Operating margin 17.40% -8.22%
EBITD margin - 51.28%
Return on average assets 1.75% -3.76%
Return on average equity 9.75% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. President
Age: 59
Bio & Compensation  - Reuters
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Bio & Compensation  - Reuters
Peter J. Blott Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Elisa A. Karlson Executive Vice President, Chief Administrative Officer
Age: 53
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development
Age: 42
Bio & Compensation  - Reuters
Steve T. Min Executive Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Ari Kellen Executive Vice President, Company Group Chairman
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Bio & Compensation  - Reuters
Martin N Mercer Executive VP, International
Bio & Compensation  - Reuters